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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A156Harpagophytum procumbens (Hp) and other plants. In the present
study we used an in vitro model of inﬂammation in OA to investigate
the therapeutic potential of Harpagoside in OA.
Methods: Primary human OA chondrocytes were isolated from the
non-affected cartilage obtained from OA patients who underwent
total knee arthroplasty. Human OA chondrocytes were cultured and
pre-treated for 2 h with Harpagoside (600 mM) and then cultured
with and without IL-1b (1-10 ng/ml). Chondrocyte viability was
assayed using CytoTox 96® Non-Radioactive Cytotoxicity Assay
(Promega). Secreted levels of IL-6 and MMP-13 in the culture super-
natants were assayed by ELISA and by immunoblotting respectively.
Total protein levels and phosphorylation levels of proteins were
measured by immunoblot analysis using speciﬁc antibodies (Cell
Signaling Technologies; Santa Cruz Biotechnology). Nuclear extracts
were prepared and used to study the effect of Harpagoside on IL-1b-
induced nuclear localization of the transcription factors NF-kB and
AP-1 by immunoblot analysis. mRNA levels were quantiﬁed using the
TaqMan assays (Life Technologies). Activation of transcription factors
NF-kB and AP-1 was analyzed by ELISA (Active Motif) and PathDetect
Cis-Reporting assays (Agilent Technologies). Data were analyzed and
plotted using Origin 6.1 software and P<0.05 was considered
signiﬁcant.
Results: Harpagoside did not showed a signiﬁcant cytotoxicity on OA
chondrocyte in vitro. Treatment of primary human OA chondrocytes
with IL-1b markedly stimulated the mRNA expression as well as pro-
tein secretion of IL-6 in the culture supernatants. In OA chondrocytes
pre-treated with Harpagoside a signiﬁcant reduction (p<0.05) in IL-
1b-induced expression of IL-6 was observed. Importantly, Harpagoside
did not inhibit the IL-1b-induced degradation of IkB and the activation
of NF-kB but suppressed the IL-1b-triggered over-expression of c-Fos,
one of the components of AP-1, in human OA chondrocytes. While
there was a signiﬁcant decrease in the IL-1b-induced nuclear levels of
c-Fos in OA chondrocytes pre-treated with Harpagoside, there was no
effect on nuclear levels of NF-kB-p-65 in IL-1b treated OA chon-
drocytes pre-treated with Harpagoside. Transcription factor activation
assays using reporter vectors also showed that Harpagoside treatment
blocked the IL-1b-induced activation of AP-1 but did not affect the NF-
kB activation.
Conclusions: Taken together, the data presented here suggests that
Harpagoside exert a signiﬁcant chondroprotective effect by inhibiting
the IL-1b-induced expression and production of IL-6 in human OA
chondrocytes. Importantly, our results identify a novel mechanism of IL-
6 suppression by Harpagoside, which involves the suppression of c-Fos
expression and activation of AP-1, that was independent of the activa-
tion of NF-kB. These data provide strong evidence in support of the
possible development of Harpagoside as a therapeutic choice to pre-
vent/retard the progression of OA.
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HDAC INHIBITOR SAHA INDUCES MCPIP1 EXPRESSION AND
SUPPRESSES IL-6 EXPRESSION IN HUMAN OA CHONDROCYTES
M.S. Makki, T.M. Haqqi. Northeast Ohio Med. Univ., Rootstown, OH, USA
Purpose: MCPIP1 is an important negative regulator of IL-6 expression
and is expressed at low levels in damaged OA cartilage. Histone
deacetylase inhibitors (HDACi) are a class of compound that has shown
promising results as a therapeutic agents in cancer. However their role
in regulating IL-6 expression in OA has not been studied. We tested
Class I and class II HDAC inhibitors on the expression of MCPIP1 and IL-6
in human OA chondrocytes.
Methods: Chondrocytes were prepared from human cartilage samples
obtained from OA patients and were treated with IL-1b in the absence
or presence of HADC inhibitors SAHA, TSA, VPA or MS-275. Gene
expression of miR-9, MCPIP1, IL-6 and other chondrocyte markers were
measured by Taqman Assay (Life Technologies) and Western blot
analysis. ELISA was performed to quantify the secreted IL-6 levels using
a kit (Booster Immunoleader, CA). MCPIP1-3’UTR reporter vector
activity was assayed using dual luciferase assay kit (Promega, Madison,
WI). Proteoglycan degradation was measured by estimating the release
of glycosaminoglycan (GAG) in the culture medium using a commer-
cially available kit (Astarte Biologics, WA).Results: In OA chondrocytes treatment with SAHA induced the
expression of MCPIP1 and the concomitant reduced expression of IL-6.
In IL-1b stimulated chondrocytes, SAHA but not other HDACi induced
the expression of MCPIP1 in OA chondrocytes. Additionally, IL-1b
stimulated OA chondrocytes in the presence of SAHA exhibited
90% ± 5% reduction in IL-6 mRNA and protein expression as measured
by Taqman assay and byWestern blot respectively. Secreted IL-6 protein
in the culture mediumwas also reduced by ~70%. OA cartilage explants
cultured in the presence of IL-1b þ SAHA showed reduced (1.8 fold)
GAG release in the culture medium compared to explants cultured with
IL-1b alone. Gene expression analysis revealed dramatic increase in the
expression of MCPIP1 and reduced expression of IL-6 in the OA cartilage
cultured in the presence of SAHA. To understand the pathway involved
in the upregulation of MCPIP1 upon SAHA treatment we treated
chondrocytes with MAPK and NF-kb inhibitors. NF-kb inhibitor BAY-11-
7082 repressed MCPIP1 expression by 90%, suggesting NF-kb pathway
may be primarily involved in the SAHA mediated upregulation of
MCPIP1 expression. As miR-9 has been shown to target the 3’UTR of the
MCPIP1 mRNA, this prompted us to investigate the expression of miR-9
upon SAHA treatment. Expression of miR-9 was inhibited by ~70% upon
SAHA treatment but this effect was not observed with other HDAC
inhibitors tested. To see the direct correlation between upregulation of
MCPIP1 and down-regulation of miR-9 upon SAHA treatment, we
employed MCPIP1-3’UTR luciferase construct containing miR-9 seed
sequence and transfected into OA chondrocytes. Upon SAHA treatment
of transfected OA chondrocytes luciferase activity was increased by
~25% compare to IL-1b treatment alone (P<0.005).
Conclusions: These data indicate that HDAC inhibitor SAHA up-regu-
lates MCPIP1 expression and suppress IL-6 expression in IL-1b-treated
OA chondrocytes. Additionally proteoglycan degradation was reduced
in SAHA treated cartilage explants. Down-regulation of miR-9, which
targets the 3’UTR of MCPIP1 mRNA indicates that SAHA induced upre-
gulation of MCPIP1 expression could be at least partially attributed to
down-regulation of miR-9 expression. Results of the present study
propose a novel therapeutic role for HDAC inhibitor SAHA for the
management of osteoarthritis.
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MIR-139 IS OVEREXPRESSED IN HUMAN OA CARTILAGE AND
REGULATES MCPIP1/IL6 EXPRESSION IN HUMAN OA
CHONDROCYTES
M.S. Makki, T.M. Haqqi. Northeast Ohio Med. Univ., Rootstown, OH, USA
Purpose: Osteoarthritis (OA) is a chronic and debilitating disease of
articulating joints. Mechanical stress on the joint is a primary reason for
OA, however genetic and environmental factors also plays critical role in
the pathogenesis of OA. Post-transcriptional regulation of cytokine is
important for mRNA turnover and tissue homeostasis. A recently
identiﬁed protein MCPIP1 (a.k.a. ZC3H12A/RegnaseA) is an important
regulator of IL-6 expression. The 3’ UTR of MCPIP1 mRNA harbors a
potential miR-139 “seed sequence”. We determined whether miR-139
target MCPIP1 mRNA and post-transcriptionally regulate expression
thereby playing a role in the expression of IL-6 in OA chondrocytes.
Methods: Human cartilage samples were obtained from OA patients
who underwent total joint arthroplasty. Chondrocytes were prepared
by sequential digestion of cartilage by pronase and collagenase. For
gene expression analysis total RNA was isolated from cultured primary
chondrocytes or from damaged or smooth region of OA cartilage using
Trizol reagent and RNeasy mini kit (Qiagen). OA chondrocytes or
immortalized human chondrocytes C28I2 cells were transfected with
200nM control miRNA or miR-9 and miR-139 mimic or inhibitor using
Amaxa Nucleofactor System (Lonza Inc., Walkersville, MD) and the
Chondrocyte Transfection kit according to the manufacturer’s protocol.
For colony formation or proliferation assay C28I2 cells were transfected
with miR-9, miR-139 alone or in combination. Cells were counted each
day by hematocytometer for proliferation or 5 days later cells were
stained with crystal violet for colony formation assay. Expression of
proliferation and apoptosis markers were detected byWestern blot and
Caspase 3/7 activity was assayed using kit essentially as described by
the manufacture (Promega, WI). MCPIP1-3’UTR luciferase activity was
measured using dual luciferase assay kit from Promega. Expression of
